| 2025-05-13 |
复牌提示：
2025-05-12 19:50:00 停牌，复牌日期 2025-05-14 00:00:01
|
| 2025-05-07 |
详情>>
股本变动：
变动后总股本5322.98万股
|
| 2025-05-07 |
详情>>
业绩披露：
2025年一季报每股收益0.01美元,归母净利润48.20万美元,同比去年增长100.92%
|
| 2025-03-25 |
详情>>
业绩披露：
2024年年报每股收益-1.1美元,归母净利润-5724.7万美元,同比去年增长73.69%
|
| 2025-03-17 |
详情>>
内部人交易：
Eatwell Victoria等共交易3笔
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.72美元,归母净利润-3772.7万美元,同比去年增长76.53%
|
| 2024-11-12 |
财报披露：
美东时间 2024-11-12 盘前发布财报
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-0.53美元,归母净利润-2779.4万美元,同比去年增长68.81%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-1.01美元,归母净利润-5267.3万美元,同比去年增长-12.02%
|
| 2024-04-25 |
股东大会：
将于2024-06-10召开股东大会
会议内容 ▼▲
- 1.To elect Denice Torres, Marcela Maus, M.D., Ph.D. and Eli Casdin as Class III members of the Board of Directors, to serve until our 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified;
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.To transact any other business that may properly come before the meeting or any adjournment thereof.
|
| 2024-03-07 |
详情>>
业绩披露：
2023年年报每股收益-4.42美元,归母净利润-2.18亿美元,同比去年增长14.39%
|
| 2024-03-07 |
详情>>
业绩披露：
2022年年报每股收益-7.13美元,归母净利润-2.54亿美元,同比去年增长13.02%
|
| 2024-03-07 |
详情>>
业绩披露：
2021年年报每股收益-12.44美元,归母净利润-2.92亿美元,同比去年增长-143.28%
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-3.31美元,归母净利润-1.61亿美元,同比去年增长30.42%
|
| 2023-08-14 |
详情>>
业绩披露：
2023年中报每股收益-1.89美元,归母净利润-8911万美元,同比去年增长45.38%
|
| 2023-05-10 |
详情>>
业绩披露：
2023年一季报每股收益-1.08美元,归母净利润-4702.1万美元,同比去年增长45.14%
|
| 2023-05-01 |
股东大会：
将于2023-06-13召开股东大会
会议内容 ▼▲
- 1.To elect Daniel S. Lynch, Sarah Glickman, and Wei Lin, M.D. as Class II members of the Board of Directors, to serve until our 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified;
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To approve an amendment to our Amended and Restated Certificate of Incorporation to limit the liability of certain officers of 2seventy bio, Inc. as permitted by recent amendments to Delaware law;
4.To transact any other business that may properly come before the meeting or any adjournment thereof.
|
| 2022-04-26 |
股东大会：
将于2022-06-08召开股东大会
会议内容 ▼▲
- 1.To elect Nick Leschly and Ramy Ibrahim, M.D. as Class I members of the Board of Directors, to serve until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified;
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.To transact any other business that may properly come before the meeting or any adjournment thereof.
|